What is BioIntelliSense?
BioIntelliSense operates at the intersection of wearable technology and clinical intelligence, providing a sophisticated Data-as-a-Service (DaaS) platform designed for continuous health monitoring. The company's core offering centers on medical-grade body sensors that capture vital signs, physiological biometrics, and symptomatic events in real-time. By transforming raw physiological data into actionable clinical insights, BioIntelliSense enables healthcare providers to monitor patients outside of traditional clinical settings, thereby improving outcomes and operational efficiency.
The firm's market position is defined by its ability to bridge the gap between consumer-grade wearables and hospital-grade diagnostic equipment. Through its integrated hardware and software ecosystem, BioIntelliSense addresses the critical need for longitudinal patient data, facilitating a more proactive approach to chronic disease management and post-acute care.
How much funding has BioIntelliSense raised?
BioIntelliSense has raised a total of $70M across 2 funding rounds:
Series A
$25M
Series B
$45M
Series A (2019): $25M with participation from Jonathan Weiner and Fresenius Medical Care North America
Series B (2021): $45M led by 7wireVentures and Pendrell
Key Investors in BioIntelliSense
7wireVentures
7wire Ventures is a specialized venture capital firm that builds and invests in early-stage digital health companies focused on creating informed and connected health consumers.
Pendrell
Pendrell Corporation is an investment and development firm that focuses on businesses with unique technologies protected by intellectual property rights across various digital and wireless sectors.
Fresenius Medical Care North America
Fresenius Medical Care North America is a leading provider of kidney care products and services, focusing on improving the quality of life for patients with chronic conditions.
What's next for BioIntelliSense?
With the recent capital infusion, BioIntelliSense is expected to prioritize the scaling of its commercial operations and the further refinement of its clinical intelligence algorithms. The company is likely to focus on deepening its integration with existing electronic health record (EHR) systems and expanding its footprint within large-scale health systems and provider networks. As the industry shifts toward value-based care, the demand for high-fidelity, continuous patient monitoring will likely drive further strategic partnerships and potential market expansion.
The firm's roadmap suggests a continued emphasis on enhancing the diagnostic capabilities of its wearable sensors, ensuring that the data captured remains both clinically relevant and easily interpretable for medical professionals. By maintaining its focus on medical-grade accuracy, BioIntelliSense is well-positioned to capture a larger share of the rapidly evolving remote patient monitoring market.
